Accueil・Liste d'Actions・Tandem Diabetes Care Inc

Tandem Diabetes Care Inc

Fermé

SecteurSoins de santé

22.7 -1.52

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

22.35

Max

22.78

Chiffres clés
By Trading Economics
Revenu	-775K -21M
Ventes	7.3M 255M
BPA	-0.31
Marge bénéficiaire	-8.316
Employés	2,500
EBITDA	4.5M -9.2M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+16.64% upside

Dividendes
By Acuity
Prochains Résultats	5 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	209M 1.6B
Ouverture précédente	24.22
Clôture précédente	22.7

Sentiment de l'Actualité

By Acuity

50%

142 / 340 Classement par Healthcare

Tandem Diabetes Care Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 20:06 UTC

Tandem Diabetes Care shares are lower today amid economic concerns following a disappointing U.S. retail sales report for July. The stock remains above its 20-day moving average.

13 août 2026, 19:16 UTC

Tandem Diabetes Care shares are trading lower today, despite broader market support and an early high. Initial jobless claims rose, indicating potential labor market softening.

12 août 2026, 19:41 UTC

News

Tandem Diabetes Care reported a narrower second-quarter loss of 31 cents per share, with revenues of $254.6 million, as shares rise since Tuesday.

11 août 2026, 19:46 UTC

News

Tandem Diabetes Care reported improved second-quarter results, including a narrower loss and increased revenue, supporting shares' advance during Tuesday's session.

10 août 2026, 19:36 UTC

News

Tandem Diabetes Care reported second-quarter revenue of $254.6 million and reaffirmed its full-year guidance of $1.08 billion, supporting a higher share price today.

7 août 2026, 20:02 UTC

News

Tandem Diabetes Care shares rose after Q2 sales of $254.6 million and adjusted EBITDA of $6.4 million exceeded forecasts, despite RBC lowering its price target to $26.

6 août 2026, 23:02 UTC

News

Tandem Diabetes Care reported Q2 sales of $254.6 million and reaffirmed revenue guidance, with shares trading higher in after-market hours.

5 août 2026, 19:56 UTC

News

Tandem Diabetes Care Inc's shares are declining amid negative sentiment in the insulin sector following Insulet Corp's lowered revenue growth forecast.

4 août 2026, 19:46 UTC

Tandem Diabetes Care Inc shares are lower today, influenced by declines in the Health Care Equipment sub-sector. Earlier, the stock reached a session high before pulling back.

31 juil. 2026, 19:51 UTC

Tandem Diabetes Care Inc is advancing today, benefiting from positive market sentiment driven by technology stocks, despite pulling back from earlier session highs.

30 juil. 2026, 17:11 UTC

Tandem Diabetes Care shares are lower today as the Health Care Equipment sub-sector declines. The asset remains above its 20-day moving average.

29 juil. 2026, 18:15 UTC

Tandem Diabetes Care Inc. shares are higher, driven by significant gains in Health Care Equipment stocks, despite a recent trend of daily price increases.

27 juil. 2026, 19:21 UTC

Tandem Diabetes Care Inc. shares are lower, reflecting broader market trends amid declining oil prices and easing geopolitical tensions ahead of the Federal Reserve meeting.

24 juil. 2026, 14:02 UTC

Tandem Diabetes Care Inc shares are lower today, with no specific news identified. Broader market concerns follow a significant sell-off on Thursday.

21 juil. 2026, 19:06 UTC

Tandem Diabetes Care is lower today, driven by declines in the Health Care Equipment sub-sector. The asset has fallen steadily after an early high.

20 juil. 2026, 17:26 UTC

Tandem Diabetes Care Inc shares are higher today, recovering from an early dip. The stock has gained significantly since last month’s close.

Comparaison

Variation de prix

Tandem Diabetes Care Inc prévision

Objectif de Prix

By TipRanks

16.64% hausse

Prévisions sur 12 Mois

Moyen 26.5 USD 16.64%

Haut 50 USD

Bas 15.5 USD

Basé sur 15 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

15 ratings

Achat

Maintien

Vente

Basé sur 15 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

142 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.